

Invitation to Shareholder Webinar Following Company Announcement

02 July 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that following the release of the licensing agreement announcement this morning, the Company will host a shareholder webinar to provide further context and commentary.

We invite shareholders and interested parties to attend the webinar and hear from Managing Director and CEO Dr Michael Thurn, and Chief Financial Officer Dan O’Connell, who will provide an overview of the agreement. The briefing will be followed by a Q&A session.

Anyone wishing to attend the webinar must register:

Date and time: 13:00pm AEST (11:00am AWST) on Wednesday, 2 July

Registration: <https://bit.ly/Neurizon5537>

Shareholders are encouraged to submit questions ahead of the event via the registration page. A recording will be made available following the session for those unable to attend live.

This webinar forms part of Neurizon’s commitment to open and transparent communication with shareholders as we continue to advance our mission of delivering meaningful progress for people living with neurodegenerative diseases.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

Dr. Michael Thurn

Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic

Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited